Name | Components | Example of uses, and other notes |
7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use | 7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) | Acute myelogenous leukemia, excluding acute promyelocytic leukemia |
ABVD | doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine | Hodgkin's lymphoma |
AC | doxorubicin (Adriamycin), cyclophosphamide | breast cancer |
BACOD | bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | Non-Hodgkin lymphomas |
BEACOPP | bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone | Hodgkin's lymphoma |
BEP | bleomycin, etoposide, platinum agent | testicular cancer, germ cell tumors |
CA | cyclophosphamide, doxorubicin (Adriamycin) (same as AC) | breast cancer |
CAF | cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU) | breast cancer |
CAPOX or XELOX | capecitabine and oxaliplatin | colorectal cancer |
CAV | cyclophosphamide, doxorubicin (Adriamycin), vincristine | lung cancer |
CBV | cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) | lymphoma |
CHOEP | cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone | Non-Hodgkin lymphomas |
CEPP | cyclophosphamide, etoposide, procarbazine, prednisone | Non-Hodgkin Lymphomas |
ChlVPP/EVA | chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) | Hodgkin's lymphoma |
CHOP | cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone | non-Hodgkin lymphoma |
CHOP-R or R-CHOP | CHOP + rituximab | B cell non-Hodgkin lymphoma |
ClaPD | clarithromycin, pomalidomide, dexamethasone | multiple myeloma |
CMF | cyclophosphamide, methotrexate, fluorouracil (5-FU) | breast cancer |
CMV | cisplatin, methotrexate, vinblastine | transitional bladder carcinoma |
COP or CVP | cyclophosphamide, Oncovin (vincristine), prednisone | non-Hodgkin lymphoma in patients with history of cardiovascular disease |
COPP | cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone | Hodgkin's lymphoma |
CT or TC | docetaxel (Taxotere), cyclophosphamide | breast cancer |
CTD | cyclophosphamide, thalidomide, dexamethasone | AL amyloidosis |
CVAD and Hyper-CVAD | cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone | aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia |
CVE | carboplatin, vincristine, etoposide | retinoblastoma |
CYBORD | cyclophosphamide, bortezomib, dexamethasone | multiple myeloma, AL amyloidosis |
DA or DAC | daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen | Acute myeloid leukemia, excluding acute promyelocytic leukemia |
DAT | daunorubicin, cytarabine (ara-C), tioguanine | Acute myeloid leukemia |
DCEP | dexamethasone, cyclophosphamide, etoposide, platinum agent | relapsed or refractory multiple myeloma |
DHAP | dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | Non-Hodgkin lymphomas |
DHAP-R or R-DHAP | dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | Non-Hodgkin lymphomas |
DICE | dexamethasone, ifosfamide, cisplatin, etoposide (VP-16) | aggressive relapsed lymphomas, progressive neuroblastoma |
DT-PACE | dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma |
EC | epirubicin, cyclophosphamide | breast cancer |
ECF (MAGIC) | epirubicin, cisplatin, fluorouracil (5-FU) | gastric cancer and cancer of the esophagogastric junction (Siewert classification III) |
EOX | epirubicin, oxaliplatin, capecitabine | esophageal Cancer, gastric Cancer |
EP | etoposide, platinum agent | testicular cancer, germ cell tumors |
EPOCH | etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin | Non-Hodgkin lymphomas |
EPOCH-R or R-EPOCH | etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab | B cell Non-Hodgkin lymphomas |
ESHAP | etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent | Non-Hodgkin lymphoma |
ESHAP-R or R-ESHAP | etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | Non-Hodgkin lymphoma |
FAM | fluorouracil, doxorubicin (Adriamycin), mitomycin | gastric cancer |
FAMTX | fluorouracil, doxorubicin (Adriamycin), methotrexate | gastric cancer |
FCM or FMC | fludarabine, cyclophosphamide, mitoxantrone | B cell non-Hodgkin lymphoma |
FCM-R or R-FCM or R-FMC or FMC-R | fludarabine, cyclophosphamide, mitoxantrone plus rituximab | B cell non-Hodgkin lymphoma |
FCR | fludarabine, cyclophosphamide, rituximab | B cell non-Hodgkin lymphoma |
FM | fludarabine, mitoxantrone | B cell non-Hodgkin lymphoma |
FM-R or R-FM or RFM or FMR | fludarabine, mitoxantrone, and rituximab | B cell non-Hodgkin lymphoma |
FEC | fluorouracil (5-FU), epirubicin, cyclophosphamide | breast cancer |
FEC-T | fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) | breast cancer |
FL (also known as Mayo) | fluorouracil (5-FU), leucovorin (folinic acid) | colorectal cancer |
FLAG | fludarabine, cytarabine, G-CSF | relapsed or refractory acute myelogenous leukemia |
FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG | fludarabine, cytarabine, idarubicin, G-CSF | relapsed or refractory acute myelogenous leukemia |
FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[citation needed] | mitoxantrone, fludarabine, cytarabine, G-CSF | relapsed or refractory acute myelogenous leukemia |
FLAMSA | fludarabine, cytarabine, amsacrine | myelodysplastic syndrome, acute myeloid leukemia |
FLAMSA-BU or FLAMSA-Bu | fludarabine, cytarabine, amsacrine, busulfan | myelodysplastic syndrome, acute myeloid leukemia |
FLAMSA-MEL or FLAMSA-Mel | fludarabine, cytarabine, amsacrine, melphalan | myelodysplastic syndrome, acute myeloid leukemia |
FLOT | fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel | esophageal cancer, gastric cancer |
FOLFIRI | fluorouracil (5-FU), leucovorin (folinic acid), irinotecan | colorectal cancer |
FOLFIRINOX | fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin | pancreatic cancer |
FOLFOX | fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin | colorectal cancer |
GC | gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin | bladder cancer |
GDP | gemcitabine, dexamethasone, cisplatin | Non-Hodgkin lymphomas and Hodgkin lymphoma |
GemOx or GEMOX | gemcitabine, oxaliplatin | Non-Hodgkin lymphomas |
GVD | gemcitabine, vinorelbine, pegylated liposomal doxorubicin | Hodgkin lymphoma |
GemOx-R or GEMOX-R or R-GemOx or R-GEMOX | gemcitabine, oxaliplatin, rituximab | Non-Hodgkin lymphomas |
IA or IAC | idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen | Acute myelogenous leukemia, excluding acute promyelocytic leukemia |
ICE | ifosfamide, carboplatin, etoposide (VP-16) | aggressive lymphomas, progressive neuroblastoma |
ICE-R or R-ICE or RICE | ICE + rituximab | high-risk progressive or recurrent lymphomas |
IFL | irinotecan, leucovorin (folinic acid), fluorouracil | colorectal cancer |
IVA | ifosfamide, vincristine, actinomycin D | rhabdomyosarcoma |
MAP or MAPIE | Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid) | Bone cancer, Osteosarcoma |
m-BACOD | methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | non-Hodgkin lymphoma |
MACOP-B | methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin | non-Hodgkin lymphoma |
MAID | mesna, doxorubicin, ifosfamide, dacarbazine | soft-tissue sarcoma |
MINE | mesna, ifosfamide, novantrone, etoposide | Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases |
MINE-R or R-MINE | mesna, ifosfamide, novantrone, etoposide plus rituximab | Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases |
MMM | mitomycin, methotrexate, mitoxantrone | breast cancer |
MOPP | mechlorethamine, vincristine (Oncovin), procarbazine, prednisone | Hodgkin's lymphoma |
MVAC | methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin | advanced bladder cancer[4] |
MVP | mitomycin, vindesine, cisplatin | lung cancer and mesothelioma |
NP | cisplatin, vinorelbine | non-small cell lung carcinoma |
PACE | platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | |
PCV | Procarbazine, CCNU (lomustine), vincristine | brain tumors |
PEB | cisplatin, etoposide, bleomycin | non-seminomatous germ cell tumors |
PEI | cisplatin, etoposide, ifosfamide | small-cell lung carcinoma |
platin + taxane[5] | cisplatin/carboplatin, paclitaxel/docetaxel | ovarian cancer |
POMP | 6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone | acute adult leukemia[6] |
ProMACE-MOPP | methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP | non-Hodgkin lymphoma |
ProMACE-CytaBOM | prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin | non-Hodgkin lymphoma |
RdC | lenalidomide (Revlimid), dexamethasone, cyclophosphamide | AL amyloidosis |
R-Benda | rituximab + bendamustine | follicular lymphoma and MALT lymphoma[7] |
R-DHAP or DHAP-R | rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma |
R-FCM or FCM-R | rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone | B cell non-Hodgkin lymphoma |
R-ICE or ICE-R or RICE | rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide | high-risk progressive or recurrent lymphomas |
RVD | lenalidomide (Revlimid), bortezomib, dexamethasone | |
Stanford V | doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone | Hodgkin lymphoma |
TAC or ACT | docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide | breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) |
TAD | tioguanine, cytarabine (ara-C), daunorubicin | acute myeloid leukemia |
TC or CT | docetaxel (Taxotere), cyclophosphamide | breast cancer |
TCH | docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) | breast cancer with positive HER2/neu receptor |
TCHP | docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) | breast cancer with positive HER2/neu receptor |
Thal/Dex | thalidomide, dexamethasone | multiple myeloma |
TIP | paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) | testicular cancer, germ cell tumors in salvage therapy |
EE-4A | vincristine, actinomycin[8] | Wilms' tumor[8] |
DD-4A | vincristine, actinomycin, doxorubicin (Adriamycin)[8] | Wilms' tumor[8] |
VABCD | vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine | MOPP refractory Hodgkin's Lymphoma |
VAC | vincristine, actinomycin, cyclophosphamide | rhabdomyosarcoma |
VAD | vincristine, doxorubicin (Adriamycin), dexamethasone | multiple myeloma |
VAMP | one of 3 combinations of vincristine and others | Hodgkin's lymphoma, leukemia, multiple myeloma |
Regimen I | vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide | Wilms' tumor[8] |
VAPEC-B | vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin | Hodgkin's lymphoma |
VDC-IE | vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide | Ewing's sarcoma |
VD-PACE | bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma |
VIFUP | vinorelbine, cisplatin, fluorouracil | locally advanced/metastatic breast cancer |
VIP | vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)[9][10] | testicular cancer, germ cell tumors |
VTD-PACE | bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | multiple myeloma |
V-DCEP | bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent | relapsed or refractory multiple myeloma |